大同市桑拿论坛-大同市桑拿论坛_第1页

在临沧酒店晚上怎么叫服务

Welcome to the official website of Yantai Dongcheng Pharmaceutical Group Co., Ltd!
Stock Code: 002675
development strategy
Your current position: home page >> About Dongcheng >>Development strategy

We are committed to the establishment of domestic pharmaceutical enterprises with the development strategy of attaching equal importance to the business of raw materials and preparations, endogenous growth and extensive expansion. The formation of the parent company as the main carrier of the API business sector, with the subsidiary companies of northern pharmaceutical and Dayang pharmaceutical as the platform of the preparation business segment.

  Taking nuclide medicine as the new core competitiveness of the enterprise, Dongcheng Pharmaceutical Co., Ltd. concentrates its advantageous resources, integrates the domestic nuclear medicine industry with the help of the capital market, and creates a full value chain industrial platform of nuclear medicine through the development idea of "getting involved in the upstream, integrating the downstream and laying out the frontier".   

  The company increases R & D investment in R & D field, enhances R & D strength, and rapidly improves the company's independent innovation ability. Focus on cardio cerebrovascular, orthopedics, marine drugs, radionuclide drugs, constantly enrich and optimize the company's product line in research.

contact us CONTACT US
0535-6391521
Switchboard: 86-535-6391521 / 6391522
Email: zxu @ midatlanticlegends.com
Address: No.7 Changbaishan Road, Yantai Development Zone, Shandong Province
Copyright 2014 Yantai Dongcheng Pharmaceutical Group Co., Ltd. All Rights Reserved Lu ICP Bei 18035060-1